Search

Your search keyword '"BENCHMRK STUDY TEAMSA"' showing total 1 results
Start Over Author "BENCHMRK STUDY TEAMSA"
1 results on '"BENCHMRK STUDY TEAMSA"'

1. Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials

Author

Steigbigel, Rt, Cooper, Da, Teppler, H, Eron, Jj, Gatell, Jm, Kumar, Pn, Rockstroh, Jk, Schechter, M, Katlama, C, Markowitz, M, Yeni, P, Loutfy, Mr, Lazzarin, A, Vullo, Vincenzo, Lennox, Jl, Clotet, B, Zhao, J, Wan, H, Rhodes, Rr, Strohmaier, Km, Barnard, Rj, Isaacs, Rd, Nguyen, By, and BENCHMRK STUDY TEAMSA

Subjects
Microbiology (medical), Male, medicine.medical_specialty, Anti-HIV Agents, Integrase inhibitor, HIV Infections, Article, Raltegravir Potassium, law.invention, Pharmacotherapy, Acquired immunodeficiency syndrome (AIDS), Randomized controlled trial, Double-Blind Method, law, Internal medicine, Drug Resistance, Viral, medicine, Humans, business.industry, Middle Aged, Viral Load, Raltegravir, medicine.disease, Pyrrolidinones, Surgery, CD4 Lymphocyte Count, Clinical trial, Infectious Diseases, HIV-1, RNA, Viral, Drug Therapy, Combination, Female, business, Viral load, medicine.drug
Abstract

BENCHMRK-1 and -2 are ongoing double-blind phase III studies of raltegravir in patients experiencing failure of antiretroviral therapy with triple-class drug-resistant human immunodeficiency virus infection. At week 96 (combined data), raltegravir (400 mg twice daily) plus optimized background therapy was generally well tolerated, with superior and durable antiretroviral and immunological efficacy, compared with optimized background therapy alone.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results